Zhitong Finance App News, Baili Tianheng (688506.SH) announced that recently, the world's first (First-in-class), Newconcept (Newconcept), the world's first and only EGFR×HER3 dual-antibody ADC approved for marketing, was included in the list of priority review varieties by the Drug Evaluation Center of the China Drug Administration (“CDE”). According to public information inquiries, Yizekang® is also the world's first EGFR×HER3 dual-antibody ADC to be included in the list of priority review varieties.

Proposed Indications (or Functional Indications): This product is suitable for patients with locally advanced or metastatic non-squamous non-small cell lung cancer with EGFR-sensitive mutations that have failed to be treated with EGFR-TKI.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.